Abstract
Hodgkin Lymphoma (HL) represents one of the most common types of a non-AIDS-defining tumour that occurs in the HIV population, and its incidence is increasing in the post Highly Active Anti-retroviral Therapy (HAART) era. Despite the aggressiveness of that disease, the outcome of patients with HIV-HL has improved with better, combined antineoplastic and antiretroviral approaches. New and effective antiretroviral drugs, in conjunction with nucleoside analogs, improve the control of the underlying HIV infection when used during treatment of HL with chemotherapy. The inclusion of hematopoietic growth factors in the treatment of patients with HIV-HL may allow for the administration of higher dose-intensity chemotherapy and the prolonged use of antiretroviral drugs, with the aim of improving the survival. In addition, new functional imaging tools, like the Positron Emission Tomography (PET), may help to guide treatment and minimize long term toxicity.
Keywords: Hodgkin lymphoma, HIV, non-AIDS-defining tumour, chemotherapy
Current HIV Research
Title: Hodgkin Lymphoma in HIV Positive Patients
Volume: 8 Issue: 2
Author(s): Nicolas Mounier, Michele Spina and Jean P. Spano
Affiliation:
Keywords: Hodgkin lymphoma, HIV, non-AIDS-defining tumour, chemotherapy
Abstract: Hodgkin Lymphoma (HL) represents one of the most common types of a non-AIDS-defining tumour that occurs in the HIV population, and its incidence is increasing in the post Highly Active Anti-retroviral Therapy (HAART) era. Despite the aggressiveness of that disease, the outcome of patients with HIV-HL has improved with better, combined antineoplastic and antiretroviral approaches. New and effective antiretroviral drugs, in conjunction with nucleoside analogs, improve the control of the underlying HIV infection when used during treatment of HL with chemotherapy. The inclusion of hematopoietic growth factors in the treatment of patients with HIV-HL may allow for the administration of higher dose-intensity chemotherapy and the prolonged use of antiretroviral drugs, with the aim of improving the survival. In addition, new functional imaging tools, like the Positron Emission Tomography (PET), may help to guide treatment and minimize long term toxicity.
Export Options
About this article
Cite this article as:
Mounier Nicolas, Spina Michele and Spano P. Jean, Hodgkin Lymphoma in HIV Positive Patients, Current HIV Research 2010; 8 (2) . https://dx.doi.org/10.2174/157016210790442704
DOI https://dx.doi.org/10.2174/157016210790442704 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
HIV vaccine development
The development of a safe and effective vaccine that impedes HIV-1 transmission and/or limits the severity of infection remains a public health priority. The HIV-1/AIDS pandemic continues to have a disproportionate impact on vulnerable and under-served communities in the USA and globally. In the USA, minority communities that have relatively ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current Perspective of Natural Alkaloid Carbazole and its Derivatives as Antitumor Agents
Anti-Cancer Agents in Medicinal Chemistry Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives
Current Cancer Drug Targets Treatment of Diffuse-Type Gastric Cancer Cells Using 213Bi-Radioimmunoconjugates In Vitro and In Vivo Following Intraperitoneal Dissemination
Current Radiopharmaceuticals Contrast-enhanced Ultrasound for Liver Imaging: Recent Advances
Current Pharmaceutical Design Programmed Cell Death after Intracerebral Hemorrhage
Current Neuropharmacology Meta Analysis of Advanced Cancer Survival Data Using Lognormal Parametric Fitting: A Statistical Method to Identify Effective Treatment Protocols
Current Pharmaceutical Design A Bottom-Up Proteomic Approach in Bone Marrow Plasma Cells of Newly Diagnosed Multiple Myeloma Patients
Current Proteomics Clinical Pharmacology of EGFR/Met Inhibitors in Non-Small Cell Lung Cancer
Current Drug Targets Genetic Variation at the Human MGMT Locus and its Biological Consequences
Current Pharmacogenomics Microwave Syntheses: A Modern Day Approach Towards Sustainable Chemistry
Current Microwave Chemistry Synthetic Lethality to Overcome Cancer Drug Resistance
Current Medicinal Chemistry Targeted Therapy of Multiple Myeloma: The Changing Paradigm at the Beginning of the New Millennium
Current Cancer Drug Targets Comprehensive DNA Methylation-transcriptome Profiles Association Analysis During the Treatment of Acute Myelocytic Leukemia
Current Pharmaceutical Design Isolation of a New Sesquiterpene Lactone From Vernonia Zeylanica (L) Less and its Anti-Proliferative Effects in Breast Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Natural Products As Antimitotic Agents
Current Topics in Medicinal Chemistry Platinum(II) and Palladium(II) Complex Compounds as Anti-cancer Drugs. Methods of Cytotoxicity Determination
Current Pharmaceutical Analysis Clinical Pharmacotherapy and Drug Development for Pulmonary Arterial Hypertension
Recent Patents on Cardiovascular Drug Discovery The Ubiquitin+Proteasome Protein Degradation Pathway as a Therapeutic Strategy in the Treatment of Solid Tumor Malignancies
Anti-Cancer Agents in Medicinal Chemistry Peptide-based Radiopharmaceuticals for Targeted Tumor Therapy
Current Medicinal Chemistry Glioblastoma Multiforme and its Cell Interruption
Current Cancer Therapy Reviews